2C-T-2

Template:Main other {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=121912CCSc1cc(OC)c(cc1OC)CCN1S/C12H19NO2S/c1-4-16-12-8-10(14-2)9(5-6-13)7-11(12)15-3/h7-8H,4-6,13H2,1-3H3HCWQGDLBIKOJPM-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data= Oral<ref name="Shulgin" />Serotonin; 5-HT₂ receptor agonist; Serotonergic psychedelic; HallucinogenNone | _legal_data=S9F2Schedule IIISchedule I

| _other_data=2-[4-(ethylsulfanyl)-2,5-dimethoxyphenyl]ethan-1-amine

| _image_0_or_2 = 2C-T-2 2DACS.svg2C-T-2 anim.gif | _image_LR =

| _datapage = 2C-T-2 (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=S9F2Schedule IIISchedule I | _ATC_prefix_supplemental=None | _has_EMA_link = | CAS_number=207740-24-7 | PubChem=12074193 | ChemSpiderID=16787961 | ChEBI= | ChEMBL=339223 | DrugBank= | KEGG=C22715 | _hasInChI_or_Key={{#if:1S/C12H19NO2S/c1-4-16-12-8-10(14-2)9(5-6-13)7-11(12)15-3/h7-8H,4-6,13H2,1-3H3HCWQGDLBIKOJPM-UHFFFAOYSA-N |yes}} | UNII=WPS2KSX2TJ | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields=verified |Watchedfields=verified |verifiedrevid=477216630}}

2C-T-2, also known as 4-ethylthio-2,5-dimethoxyphenethylamine, is a psychedelic and entactogenic phenethylamine of the 2C family.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It was first synthesized in 1981 by Alexander Shulgin, and rated by him as one of the "magical half-dozen" most important psychedelic phenethylamine compounds.<ref name="Theobald">Template:Cite journal</ref><ref name="Shulgin">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The drug has structural and pharmacodynamic properties similar to those of 2C-T-7 ("Blue Mystic").

Dosage

In Alexander Shulgin's book PiHKAL, the dosage range is listed as 12 to 25 mg.<ref name="Shulgin" />

Pharmacology

Template:Nowrap

Target	Affinity (Ki, nM)
5-HT1A	370–1,740 (Ki) 3,000 (Template:Abbrlink) 76% (Template:Abbrlink)
5-HT1B	858
5-HT1D	86
5-HT1E	415
5-HT1F	Template:Abbr
5-HT2A	9–40 (Ki) 0.354–80 (Template:Abbr) 67–107% (Template:Abbr)
5-HT2B	6–69 (Ki) 130 (Template:Abbr) 75% (Template:Abbr)
5-HT2C	14–54 (Ki) 0.0233–3.8 (Template:Abbr) 87–107% (Template:Abbr)
5-HT3	>10,000
5-HT4	Template:Abbr
5-HT5A	>10,000
5-HT6	1,362
5-HT7	969
α1A	17,000
α1B	>10,000
α1D	Template:Abbr
α2A	230–730
α2B	982
α2C	166
β1	9,202
β2	1,184
β3	Template:Abbr
D1	15,000
D2	2,795–5,100
D3	1,835–11,000
D4	>10,000
D5	>10,000
H1–H4	>10,000
M1	>10,000
M2	>10,000
M3	692
M4	>10,000
M5	1,502
I1	2,080
σ1	3,870
σ2	>10,000
Template:Abbrlink	2,200 (Ki) (mouse) 40 (Ki) (rat) 96 (Template:Abbr) (mouse) 4,300 (Template:Abbr) (rat) >10,000 (Template:Abbr) (human) 54% (Template:Abbr) (mouse) 86% (Template:Abbr) (rat)
Template:Abbrlink	13,000 (Ki) 62,000 (Template:Abbrlink) Template:Abbr (Template:Abbr)
Template:Abbrlink	>30,000 (Ki) 153,000 (Template:Abbr) Template:Abbr (Template:Abbr)
Template:Abbrlink	>30,000 (Ki) 332,000 (Template:Abbr) Template:Abbr (Template:Abbr)
Template:Abbrlink	Template:Abbr (Template:Abbr)
Template:Abbrlink	Template:Abbr (Template:Abbr)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: <ref name="PDSPKiDatabase">{{#invoke:citation/CS1|citation		CitationClass=web }}</ref><ref name="Ray2010">Template:Cite journal</ref><ref name="RickliLuethiReinisch2015">Template:Cite journal</ref><ref name="EshlemanForsterWolfrum2014">Template:Cite journal</ref><ref name="PottieCannaertStove2020">Template:Cite journal</ref><ref name="WagmannBrandtStratford2019">Template:Cite journal</ref><ref name="SimmlerBuchyChaboz2016">Template:Cite journal</ref>

The mechanism of action that produces 2C-T-2’s hallucinogenic and entheogenic effects is shown to be most likely a result from action as a 5-HT_2A, 5-HT_2B, and 5-HT_2C serotonin receptor agonist,<ref>Template:Cite journal</ref> a mechanism of action shared by the hallucinogenic tryptamines and phenethylamines to varying degrees.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> 2C-T-2 has also shown to be a partial agonist of adrenergic receptors.<ref>Template:Cite journal</ref>

Dangers

A potential risk of neurotoxicity from 2C-T-2 use (and 2C chemical series in general) has been shown in serotonergic and dopaminergic containing neurons. This has also been shown to be magnified in serotonergic-containing cells with combined use of 2C series drugs with alcohol, MDMA, and methamphetamine.<ref>Template:Cite journal</ref>

Severe 'intoxication' on 2C series drugs has been observed as behavior that includes: intense hallucinations, agitation, aggression, violence, dysphoria, hypertension, tachycardia, seizures, and hyperthermia.<ref>Template:Cite journal</ref>

Interactions

2C-T-2 is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B.<ref name="DeanStellpflugBurnett2013">Template:Cite journal</ref><ref name="TheobaldMaurer2007">Template:Cite journal</ref> Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-T-2.<ref name="DeanStellpflugBurnett2013" /><ref name="TheobaldMaurer2007" /><ref name="HalmanKongSarris2024">Template:Cite journal</ref> This may result in overdose and serious toxicity.<ref name="HalmanKongSarris2024" /><ref name="DeanStellpflugBurnett2013" />

Legal status

Argentina

2C-T-2 is also a controlled substance in Argentina as well as 2C-B and 2C-I.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Canada

As of October 31, 2016, 2C-T-2 is a controlled substance (Schedule III) in Canada.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

China

As of October 2015 2C-T-2 is a controlled substance in China.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Netherlands

The Netherlands became the first country in the world to ban 2C-T-2, and classify it as a hard drug, by law. In April, 1999, 2C-T-2 became a list I drug of the Opium Law.

Sweden

Schedule I in Sweden.

2C-T-2 was first classified as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of April 1, 1999, under SFS 1999:58<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> that made it illegal to sell or possess.

The Riksdag added 2C-T-2 to Narcotic Drugs Punishments Act under Swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of March 16, 2004, published by Medical Products Agency (MPA) in regulation LVFS 2004:3 listed as 2C-T-2, 2,5-dimetoxi-4-etyltiofenetylamin.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

United Kingdom

2C-T-2 and all other compounds featured in PiHKAL are illegal drugs in the United Kingdom.

United States

2C-T-2 is specifically listed as a schedule I substance under SEC. 1152 of S.3187: Food and Drug Administration Safety and Innovation Act of 2012.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Australia

2C-T-2 is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015).<ref name="Poisons Standard">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.<ref name="Poisons Standard" />

See also

• 2C-T
• 2C-T-4
• 2C-T-7
• Aleph-2

External links

• 2C-T-2 - Isomer Design
• 2C-T-2 - PsychonautWiki
• 2C-T-2 vault - Erowid
• 2C-T-2 - PiHKAL - Erowid
• 2C-T-2 - PiHKAL - Isomer Design
• 2C-T-2: Potential Therapeutic Alternative to MDMA?
• Sulfurous Samadhi: An Investigation of 2C-T-2 & 2C-T-7 - Erowid

Template:Psychedelics Template:Serotonin receptor modulators Template:TAAR modulators {{#invoke:Navbox|navbox}}